PT  - JOURNAL ARTICLE
AU  - Sergio Kaiser
AU  - Luqing Zhang
AU  - Brit Mollenhauer
AU  - Jaison Jacob
AU  - Simonne Longerich
AU  - Jorge Del-Aguila
AU  - Jacob Marcus
AU  - Neha Raghavan
AU  - David Stone
AU  - Olumide Fagboyegun
AU  - Douglas Galasko
AU  - Mohammed Dakna
AU  - Bilada Bilican
AU  - Mary Dovlatyan
AU  - Anna Kostikova
AU  - Jingyao Li
AU  - Brant Peterson
AU  - Michael Rotte
AU  - Vinicius Sanz
AU  - Tatiana Foroud
AU  - Karla Gonzalez
AU  - Samantha J. Hutten
AU  - Mark Frasier
AU  - Hirotaka Iwaki
AU  - Andrew Singleton
AU  - Ken Marek
AU  - Karen Crawford
AU  - Fiona Elwood
AU  - Mirko Messa
AU  - Pablo Serrano-Fernandez
TI  - Parkinson’s disease causality and heterogeneity: a proteogenomic view
AID  - 10.1101/2022.03.09.22272131
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.09.22272131
4099  - http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272131.short
4100  - http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272131.full
AB  - Pathogenesis and clinical heterogeneity in Parkinson’s disease (PD) have been evaluated from genetic, pathological, and clinical perspective. Technology allowing for high-throughput proteomic analyses in cerebrospinal fluid (CSF) has opened new opportunities to scrutinize this heterogeneity. This is to date the most comprehensive proteomics profiling in CSF of PD patients and controls, both in terms of subjects (n=1103) and proteins (n=4135).Combining CSF aptamer-based proteomics with genetics across all samples we determined the protein quantitative trait loci (pQTLs) linking genetic variants with protein abundance in CSF. Analyzing pQTLs together with summary statistics from the largest PD genome wide association study (GWAS) led us to identify 68 potential causal proteins by Mendelian randomization. The top PD causal protein, GPNMB, has colocalization support and has been reported to be upregulated in the substantia nigra of PD patients.We also examined three subcohorts of PD patients: LRRK2 variant carriers (LRRK2+), GBA variant carriers (GBA+) and idiopathic PD patients, each with their respective controls. The second goal was to identify proteomic differences between PD patients and controls within and between the three subcohorts. Statistical analyses revealed six proteins differentially expressed when comparing GBA+ PD patients with unaffected GBA+ controls, seven proteins when comparing LRRK2+ PD patients with unaffected LRRK2+ controls and 23 proteins when comparing idiopathic PD patients with healthy controls who did not carry any severe PD mutations.Furthermore a hypothesis-free stratification of idiopathic PD patients based on their proteomic profile revealed two protein modules based on the co-expression network structure. Based on these modules, cluster analysis revealed two patient endotypes for idiopathic PD.Differences in the CSF proteomic signature between subcohorts and between idiopathic endotypes, as well as causal targets identified using both proteomics and genetics may together influence the way we approach the identification of potential therapeutic targets in PD.Competing Interest StatementThe study was supported by the Novartis Institutes for Biomedical Research and Merck. Protein measurements were performed at SomaLogic. A.K., B.B., B.P. F.E., J.J., J.L., L.Z., M. Dovlatyan, M.M., M.R., P.S-F., S.K. and V.S. are or have been employees of Novartis; J.J., S.K., M.M. are also stockholders of Novartis. D.S., J.D-A., J.M., N.R. and S.L. are or have been employees of Merck. All other authors have no conflict of interests to declare.Funding StatementThe study was supported by the Novartis Institutes for Biomedical Research and Merck.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The samples we have used for the study are available in the PPMI repositoryI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results of the current study are publicly available on the LONI database and all data produced in the present work are contained in the manuscript